πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

314 results for β€œcells” Clear

  1. umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cartilage Damage

    phase 2 mab active

    1 trial

  2. umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral Arterial Disease

    phase 2 mab completed

    1 trial

  3. 19(T2)28z1xx CAR T cells

    Takeda

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule active

    1 trial

  4. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  5. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1)

    Celgene Europe Limited

    Systemic Sclerosis, Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathy, Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial

  6. A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  7. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  8. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  9. A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants

    Hoffmann-La Roche

    Not Applicable (N/A)

    phase 1 other active

    1 trial

  10. A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and AlzheimerΒ΄s disease.

    The George Institute

    AlzheimerΒ΄s disease

    phase 1 other active

    1 trial

  11. A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

    The George Institute

    Refractory metastatic Her2 positive breast cancer

    phase 1 other active

    1 trial

  12. ADCLEC.syn1 CAR T cells

    Takeda

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  13. Allogeneic Cardiosphere-Derived Cells (CDCs)

    CAPRICOR THERAPEUTICS, INC.

    Dilated Cardiomyopathy (DCM)

    phase 1 mab active

    1 trial

  14. Allogeneic MSC

    United Therapeutics Europe Ltd

    Mesenchymal Stromal Cells

    phase 1 mab completed

    1 trial

  15. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Ξ³Ξ΄ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial

  16. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam Therapeutics

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  17. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  18. Anti-CD123 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    AML (Acute Myeloid Leukemia)

    phase 1 small molecule active

    1 trial

  19. Anti-CD19 UCAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Dermatomyositis, Juvenile

    phase 1 small molecule active

    1 trial

  20. Anti-CD19 Universal CAR-T Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  21. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  22. Anti-CD5 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    T-ALL/Lymphoma

    phase 1 mab active

    1 trial

  23. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  24. Anti-CLL1 CART cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources